WEBSITE BSE:590021 NSE : BHARAT RA(PS 28 Nov, 16:01
Market Cap ₹3772 Cr.
Stock P/E 48.9
P/B 4.2
Current Price ₹9077.5
Book Value ₹ 2180.1
Face Value 10
52W High ₹11793
Dividend Yield 0.02%
52W Low ₹ 8299
Bharat Rasayan Ltd is an totally India-based company engaged in manufacturing of insecticides-technical, formulations and its intermediates. The Company in the main gives Metaphenoxy Benzaldehyde. The Company's products are Insecticides, which include Acetamiprid, Bifenthrin, Chlorpyrifos, Cypermethrin, Imidacloprid, Permethrin and Thiamethoxam; Herbicides, which consist of Clodinafop Propargyl, Cloquintocet Mexyl (Safener), Diuron and Metsulfuron Methyl; Fungicides, which consist of Tricyclazole and Myclobutanil; Acaricide, which consist of Fenpyroximate, and Intermediates, which consist of Meta Phenoxy Benzaldehyde and Para Chloro Benzyl Cyanide. The Company's plants are positioned at Rohtak, Haryana and Bharuch, Gujarat. The Company's plant at Haryana, has a ability of 5,000 metric tons (MT)/annum and additionally facilities for bulk packaging of formulations.
Price goes above X
Price falls below X
₹ | |
#(Fig in Cr.) | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 252 | 269 | 335 | 445 | 327 | 292 | 309 | 306 | 239 | 263 |
Other Income | 3 | 3 | 3 | 7 | 8 | 4 | 6 | 1 | 2 | 4 |
Total Income | 255 | 272 | 338 | 452 | 335 | 296 | 315 | 307 | 242 | 267 |
Total Expenditure | 194 | 229 | 265 | 358 | 274 | 256 | 257 | 251 | 234 | 248 |
Operating Profit | 61 | 43 | 73 | 94 | 61 | 40 | 59 | 56 | 8 | 19 |
Interest | 1 | 1 | 2 | 3 | 2 | 1 | 2 | 1 | 0 | 1 |
Depreciation | 6 | 6 | 7 | 7 | 6 | 7 | 7 | 7 | 6 | 6 |
Exceptional Income / Expenses | -0 | -0 | -3 | -1 | -1 | -1 | -1 | -0 | 0 | -0 |
Profit Before Tax | 54 | 36 | 61 | 83 | 52 | 31 | 49 | 48 | 1 | 12 |
Provision for Tax | 14 | 9 | 16 | 19 | 13 | 8 | 13 | 15 | 1 | 4 |
Profit After Tax | 40 | 27 | 46 | 65 | 39 | 23 | 37 | 33 | 1 | 8 |
Adjustments | -0 | -0 | 0 | 0 | -1 | -0 | -3 | -2 | 6 | -2 |
Profit After Adjustments | 39 | 26 | 46 | 65 | 38 | 23 | 34 | 30 | 7 | 6 |
Adjusted Earnings Per Share | 95 | 63.7 | 110.4 | 155.4 | 90.6 | 55.2 | 81.3 | 72.8 | 17.1 | 14.4 |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|---|
Net Sales | 992 | 1215 | 1092 | 1301 | 1234 | 1117 |
Other Income | 3 | 17 | 7 | 16 | 19 | 13 |
Total Income | 995 | 1232 | 1099 | 1317 | 1254 | 1131 |
Total Expenditure | 805 | 985 | 852 | 1049 | 1037 | 990 |
Operating Profit | 190 | 247 | 247 | 267 | 217 | 142 |
Interest | 16 | 16 | 4 | 7 | 6 | 4 |
Depreciation | 17 | 22 | 26 | 25 | 26 | 26 |
Exceptional Income / Expenses | -2 | -3 | -1 | -0 | -5 | -1 |
Profit Before Tax | 155 | 205 | 216 | 234 | 174 | 110 |
Provision for Tax | 44 | 48 | 51 | 58 | 49 | 33 |
Profit After Tax | 112 | 158 | 164 | 176 | 125 | 79 |
Adjustments | 0 | 0 | -1 | 0 | 0 | -1 |
Profit After Adjustments | 112 | 158 | 164 | 176 | 125 | 77 |
Adjusted Earnings Per Share | 262.5 | 371 | 385.7 | 423.5 | 299.9 | 185.6 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | -5% | 1% | 0% | 0% |
Operating Profit CAGR | -19% | -4% | 0% | 0% |
PAT CAGR | -29% | -8% | 0% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | -10% | -1% | 11% | 49% |
ROE Average | 15% | 21% | 25% | 25% |
ROCE Average | 19% | 26% | 28% | 28% |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Shareholder's Funds | 409 | 564 | 727 | 770 | 893 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 |
Borrowings | 40 | 22 | 0 | 1 | 0 |
Other Non-Current Liabilities | 14 | 12 | 10 | 10 | 10 |
Total Current Liabilities | 293 | 153 | 170 | 309 | 173 |
Total Liabilities | 756 | 752 | 908 | 1090 | 1076 |
Fixed Assets | 150 | 203 | 191 | 228 | 225 |
Other Non-Current Assets | 42 | 30 | 67 | 61 | 58 |
Total Current Assets | 564 | 519 | 650 | 801 | 793 |
Total Assets | 756 | 752 | 908 | 1090 | 1076 |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 1 | 6 | 46 | 27 | 0 |
Cash Flow from Operating Activities | -52 | 263 | 170 | -65 | 213 |
Cash Flow from Investing Activities | -48 | -68 | -153 | 51 | -61 |
Cash Flow from Financing Activities | 102 | -169 | -40 | -25 | -152 |
Net Cash Inflow / Outflow | 3 | 25 | -22 | -39 | 1 |
Closing Cash & Cash Equivalent | 6 | 46 | 27 | 0 | 19 |
# | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Earnings Per Share (Rs) | 262.49 | 371.04 | 385.7 | 423.53 | 299.89 |
CEPS(Rs) | 302.25 | 422.68 | 447.73 | 483.55 | 362.52 |
DPS(Rs) | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
Book NAV/Share(Rs) | 962.19 | 1327.74 | 1711.78 | 1853.14 | 2149.86 |
Core EBITDA Margin(%) | 18.9 | 18.93 | 22 | 19.33 | 16.01 |
EBIT Margin(%) | 17.28 | 18.24 | 20.18 | 18.52 | 14.59 |
Pre Tax Margin(%) | 15.64 | 16.89 | 19.78 | 17.96 | 14.1 |
PAT Margin (%) | 11.24 | 12.97 | 15.06 | 13.53 | 10.1 |
Cash Profit Margin (%) | 12.94 | 14.78 | 17.42 | 15.44 | 12.2 |
ROA(%) | 14.76 | 20.91 | 19.82 | 17.62 | 11.51 |
ROE(%) | 27.28 | 32.41 | 25.47 | 23.51 | 14.98 |
ROCE(%) | 26.14 | 33.74 | 30.53 | 27.87 | 19.31 |
Receivable days | 102.67 | 79.56 | 91.28 | 106.5 | 116.62 |
Inventory Days | 77.34 | 55.66 | 54.96 | 62.52 | 88.76 |
Payable days | 23.79 | 18.23 | 26.8 | 28.02 | 31.1 |
PER(x) | 15.93 | 14.04 | 24.39 | 28.76 | 30.32 |
Price/Book(x) | 4.35 | 3.92 | 5.49 | 6.57 | 4.23 |
Dividend Yield(%) | 0.04 | 0.03 | 0.02 | 0.01 | 0.02 |
EV/Net Sales(x) | 2.03 | 1.86 | 3.68 | 4.02 | 3.06 |
EV/Core EBITDA(x) | 10.6 | 9.14 | 16.26 | 19.57 | 17.39 |
Net Sales Growth(%) | 0 | 22.46 | -10.15 | 19.16 | -5.12 |
EBIT Growth(%) | 0 | 29.27 | -0.58 | 9.38 | -25.28 |
PAT Growth(%) | 0 | 41.35 | 4.33 | 7 | -29.19 |
EPS Growth(%) | 0 | 41.35 | 3.95 | 9.81 | -29.19 |
Debt/Equity(x) | 0.6 | 0.17 | 0.08 | 0.23 | 0.03 |
Current Ratio(x) | 1.92 | 3.38 | 3.82 | 2.59 | 4.6 |
Quick Ratio(x) | 1.21 | 2.33 | 2.83 | 1.7 | 2.72 |
Interest Cover(x) | 10.51 | 13.48 | 49.91 | 32.82 | 29.56 |
Total Debt/Mcap(x) | 0.14 | 0.04 | 0.01 | 0.03 | 0.01 |
# | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 75.05 | 75.05 | 75.05 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 |
FII | 0 | 0.27 | 0.25 | 0.26 | 0.32 | 0.53 | 0.39 | 0.34 | 0.35 | 0.35 |
DII | 1.72 | 1.85 | 2.03 | 2.58 | 2.57 | 2.57 | 2.6 | 2.57 | 2.57 | 2.57 |
Public | 23.23 | 22.84 | 22.67 | 22.18 | 22.11 | 21.91 | 22.02 | 22.1 | 22.09 | 22.09 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 |
FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Public | 0.1 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
See More Unlisted Share Articles
You May Also Know About